Overview

Gemcitabine for Marginal Zone Lymphoma

Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Marginal zone lymphoma, one of the indolent lymphoma, is believed to be incurable with chemotherapy. Thus the investigators need a novel agent for marginal zone lymphoma. Gemcitabine has been tried as one of salvage chemotherapy regimen and has been shown to have anti-lymphoma activity. To the investigators' knowledge, there has been no trial of gemcitabine for marginal zone lymphoma. Thus the investigators made a plan to investigate the role of gemcitabine in marginal zone lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
Eli Lilly and Company
Treatments:
Gemcitabine